Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J. Sullivan, Timothy Panella, Meredith McKean, Edgardo S. Santos, Jill Clancy, Anna Polli, Alessandra di Pietro, Paolo A. Ascierto

Cancer Res (2023) 83 (8_Supplement): CT069.

https://doi.org/10.1158/1538-7445.AM2023-CT069

Published: 14 April 2023

View article titled, Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Journal Articles

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Reinhard Dummer, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean-Jacques Grob, David C. Portnoy, Celeste Lebbe, Muhammad A. Khattak, Jonathan Cohen, Gil Bar-Sela, Inderjit Mehmi, Ronnie Shapira Frommer, Nicolas Meyer, Yixin Ren, Mizuho Fukunaga-Kalabis, Clemens Krepler, Georgina V. Long

Cancer Res (2023) 83 (8_Supplement): CT002.

https://doi.org/10.1158/1538-7445.AM2023-CT002

Published: 14 April 2023

View article titled, Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Journal Articles

Abstract 3268: Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment

Hongxu Chen, Shensi Shen, Sara Faouzi, Alexia Alfaro, Dorothee Baille, Séverine Roy, Naima Benannoune, Hugues Hermann, Samad Muhammadnejad, Stephan Vagner, Caroline Robert

Cancer Res (2023) 83 (7_Supplement): 3268.

https://doi.org/10.1158/1538-7445.AM2023-3268

Published: 04 April 2023

View article titled, Abstract 3268: Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment

Journal Articles

Abstract 2177: Roles of lactate dehydrogenase (LDH) in melanoma: an underestimated prognostic biomarker

Laura Soumoy, Virginie Quidville, Lisa Fredeau, Giuseppina Claps, Caroline Pradon, Ludovic Lacroix, Emilie Routier, Djaouida Belkadi, Séverine Roy, Feras Chehade, Stephan Vagner, Caroline Robert

Cancer Res (2023) 83 (7_Supplement): 2177.

https://doi.org/10.1158/1538-7445.AM2023-2177

Published: 04 April 2023

View article titled, Abstract 2177: Roles of lactate dehydrogenase (LDH) in melanoma: an underestimated prognostic biomarker

Journal Articles

Abstract 4167: Translational control of T cell exhaustion in melanoma, perspectives in therapeutics

Samad Muhammadnejad, Biswendu Biswas, Ramdane Guemiri, Naima Benannoune, Jérémy Lavigne, Virginie Quidville, Jean-Yves Scoazec, Stephan Vagner, Caroline Robert

Cancer Res (2023) 83 (7_Supplement): 4167.

https://doi.org/10.1158/1538-7445.AM2023-4167

Published: 04 April 2023

View article titled, Abstract 4167: Translational control of T cell exhaustion in melanoma, perspectives in therapeutics

Journal Articles

Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

Jana Biermann, Yiping Wang, Linyue Fan, Patricia Ho, Amit D. Amin, Johannes C. Melms, Somnath Tagore, Kevin Hoffer-Hawlik, Parin Shah, Neha Shaikh, Priyanka Ramaradj, Mingxuan Zhang, Antoni Ribas, Caroline Robert, Elham Azizi, Benjamin Izar

Cancer Res (2023) 83 (7_Supplement): 109.

https://doi.org/10.1158/1538-7445.AM2023-109

Published: 04 April 2023

View article titled, Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

Journal Articles

Abstract 4282: Total RNA sequencing of frozen biopsies combined to k-mer sequence analysis identify new hallmarks of immune checkpoint therapy response in melanoma

Hugues Hermann, Séverine Roy, Sandrine Agoussi, Emilie Routier, Céline Boutros, Djaouida Belkadi, Haoliang Xue, Antoine Lainé, Stephan Vagner, Daniel Gautheret, Caroline Robert

Cancer Res (2023) 83 (7_Supplement): 4282.

https://doi.org/10.1158/1538-7445.AM2023-4282

Published: 04 April 2023

View article titled, Abstract 4282: Total RNA sequencing of frozen biopsies combined to k-mer sequence analysis identify new hallmarks of immune checkpoint therapy response in melanoma

Journal Articles

Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma

Cancer Res (2022) 82 (12_Supplement): CT109.

https://doi.org/10.1158/1538-7445.AM2022-CT109

Published: 15 June 2022

View article titled, Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma

Journal Articles

Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma

Cancer Res (2022) 82 (12_Supplement): CT107.

https://doi.org/10.1158/1538-7445.AM2022-CT107

Published: 15 June 2022

View article titled, Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma

Journal Articles

Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

Cancer Res (2022) 82 (12_Supplement): CT014.

https://doi.org/10.1158/1538-7445.AM2022-CT014

Published: 15 June 2022

View article titled, Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

Journal Articles

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Cancer Res (2022) 82 (12_Supplement): 6403.

https://doi.org/10.1158/1538-7445.AM2022-6403

Published: 15 June 2022

View article titled, Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Journal Articles

Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer

Cancer Res (2022) 82 (12_Supplement): 1251.

https://doi.org/10.1158/1538-7445.AM2022-1251

Published: 15 June 2022

View article titled, Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer

Journal Articles

The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance

Michaël Cerezo, Caroline Robert, Lunxu Liu, Shensi Shen

Cancer Res (2021) 81 (22): 5596–5604.

https://doi.org/10.1158/0008-5472.CAN-21-1466

Published: 15 November 2021

View article titled, The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance

Journal Articles

Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Cancer Res (2021) 81 (13_Supplement): CT233.

https://doi.org/10.1158/1538-7445.AM2021-CT233

Published: 01 July 2021

View article titled, Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Journal Articles

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Cancer Res (2021) 81 (13_Supplement): CT004.

https://doi.org/10.1158/1538-7445.AM2021-CT004

Published: 01 July 2021

View article titled, Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Journal Articles

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAF^V600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

Grant A. McArthur, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy Moiseevich Manikhas, Yibing Yan, K. C. Huang, Anne Uyei, Virgina McNally, Ralf Gutzmer, Paolo Ascierto

Cancer Res (2020) 80 (16_Supplement): CT012.

https://doi.org/10.1158/1538-7445.AM2020-CT012

Published: 15 August 2020

View article titled, Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

Journal Articles

Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma

Adil Daud, Matteo S. Carlino, Antoni Ribas, Ana Arance, Jean-Jacques Grob, James Larkin, Georgina V. Long, Jacob Schachter, Andrea L. Webber, Clemens Krepler, Chunsheng Zhang, Jared Lunceford, Razvan Cristescu, Qing Zhao, Junshui Ma, Caroline Robert

Cancer Res (2020) 80 (16_Supplement): 2009.

https://doi.org/10.1158/1538-7445.AM2020-2009

Published: 15 August 2020

View article titled, Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma

Journal Articles

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Caroline Robert, Reinhard Dummer, Ana Arance, Antoni Ribas, Jeffrey Weber, Georgina V. Long, John Haanen, Paul Nathan, Paolo A. Ascierto, Eduard Gasal, Anthony D'Amelio, Severine Bettinger, Aislyn D. Boran, Dirk Schadendorf

Cancer Res (2019) 79 (13_Supplement): CT120.

https://doi.org/10.1158/1538-7445.AM2019-CT120

Published: 01 July 2019

View article titled, Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Journal Articles

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

Cancer Res (2019) 79 (13_Supplement): CT188.

https://doi.org/10.1158/1538-7445.AM2019-CT188

Published: 01 July 2019

View article titled, Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

Journal Articles

Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

Antoni Ribas, Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Matteo S. Carlino, James Larkin, Andrea L. Webber, Jared Lunceford, Qing Zhao, Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Wendy Blumenschein, Clemens Krepler, Nageatte Ibrahim, Adil Daud, Jean-Jacques Grob

Cancer Res (2019) 79 (13_Supplement): 4217.

https://doi.org/10.1158/1538-7445.AM2019-4217

Published: 01 July 2019

View article titled, Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

NARROW

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Abstract 3268: Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment

Abstract 2177: Roles of lactate dehydrogenase (LDH) in melanoma: an underestimated prognostic biomarker

Abstract 4167: Translational control of T cell exhaustion in melanoma, perspectives in therapeutics

Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

Abstract 4282: Total RNA sequencing of frozen biopsies combined to k-mer sequence analysis identify new hallmarks of immune checkpoint therapy response in melanoma

Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma

Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma

Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer

The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance

Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAF^V600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma

Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only